Candel Therapeutics, Inc. cotiza a 9.27 USD y tiene una capitalización bursátil de $679M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.14 | $-0.29 |
| Estimado | $-0.31 | $-0.23 | $-0.33 | $-0.23 |
| Sorpresa | — | — | +57.6% | -26.1% |
| Métrica | CADL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -73.5% | -40.4% | -33.1% |
| ROA | -30.5% | -32.0% | +1.5% |
| Current Ratio | 13.49 | 2.84 | +10.65 |
| Debt / Equity | — | 0.28 | — |